Antilysophosphatidic Acid Antibodies in the Treatment of Post-TBI Neuropathic Pain

Abstract

Lysophosphatidic Acid (LPA) is a lipid inflammatory mediator that is released following nerve injury, including traumatic brain injury (TBI). The accumulation of LPA appears to be underly at least some aspects of the sequelae to TBI, including pain and cognitive dysfunction. The goal of this project is to evaluate the therapeutic potential of a novel anti-LPA antibody (Lpathomab) for attenuating post-TBI pain. Thus, we propose to study the effect of Lpathomab, in preventing long-term pain sequelae due to fluid percussion-induced neurotrauma in rats. Nasal administration of Lpathomab, when compared to vehicle, produced significant levels in the brain of rats post TBI and produced a significant attenuation of the pain state following this injury.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Apr 01, 2019
Accession Number
AD1094292

Entities

People

  • David C Yeomans

Organizations

  • Stanford University

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Biomedical Research
  • Brain Injuries
  • Cells
  • Commerce
  • Contracts
  • Department Of Defense
  • Electronic Mail
  • Health Services
  • Instructions
  • Laboratory Animals
  • Medical Personnel
  • Nervous System
  • Pain
  • Recombinant Dna
  • Standards
  • Traumatic Stress Disorder
  • Websites

Fields of Study

  • Medicine

Readers

  • Neurotrauma and Rehabilitation Medicine.
  • Prostate Cancer Biology.